Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis
MD Ward, DE Jones, MD Goldman - Multiple Sclerosis and Related …, 2016 - Elsevier
MD Ward, DE Jones, MD Goldman
Multiple Sclerosis and Related Disorders, 2016•ElsevierAbstract Fingolimod (Gilenya, Novartis) is an oral sphingosine-1-phosphate analogue used
in the treatment of relapsing multiple sclerosis (MS). Fingolimod treatment is associated with
relative lymphopenia and was associated with an increased risk of herpes infection in
clinical trials. In the post-marketing setting, fingolimod has been associated with several
cases of cryptococcal meningitis, recently prompting an update to its prescribing information.
To date, all cases have been associated with active treatment with fingolimod. In this report …
in the treatment of relapsing multiple sclerosis (MS). Fingolimod treatment is associated with
relative lymphopenia and was associated with an increased risk of herpes infection in
clinical trials. In the post-marketing setting, fingolimod has been associated with several
cases of cryptococcal meningitis, recently prompting an update to its prescribing information.
To date, all cases have been associated with active treatment with fingolimod. In this report …
Abstract
Fingolimod (Gilenya, Novartis) is an oral sphingosine-1-phosphate analogue used in the treatment of relapsing multiple sclerosis (MS). Fingolimod treatment is associated with relative lymphopenia and was associated with an increased risk of herpes infection in clinical trials. In the post-marketing setting, fingolimod has been associated with several cases of cryptococcal meningitis, recently prompting an update to its prescribing information. To date, all cases have been associated with active treatment with fingolimod. In this report, we describe the first case of cryptococcal meningitis diagnosed after fingolimod discontinuation.
Elsevier